Volume 13, Number 1—January 2007
Research
Model for Assessing Human Papillomavirus Vaccination Strategies
Elamin H. Elbasha*
, Erik J. Dasbach*, and Ralph P. Insinga*
, Erik J. Dasbach*, and Ralph P. Insinga*Table 1
Cost-effectiveness analysis of alternative HPV vaccination strategies*
| Discounted total | Incremental | ||||
|---|---|---|---|---|---|
| Strategy | Costs | QALY | Costs | QALY | $/QALY† |
| No vaccination | 72,659,302 | 2,698,711 | –– | –– | –– |
| 12-y-old girls | 74,042,990 | 2,699,178 | 1,383,687 | 467 | 2,964 |
| 12-y-old girls and boys | 78,707,825 | 2,699,327 | 4,664,835 | 149 | Dominated |
| 12-y-old girls plus 12- to 24-y-old females catch-up | 74,815,667 | 2,699,343 | –3,892,159 | 16 | 4,666 |
| 12-y-old girls and boys plus 12− to 24-y-old females catch-up | 79,746,357 | 2,699,461 | 4,930,690 | 118 | 41,803 |
| 12-y-old girls and boys plus 12− to 24-y-old females and males catch-up | 81,761,210 | 2,699,506 | 2,014,853 | 45 | 45,056 |
*Assumes cost of vaccination series is US $360 and duration of protection is lifelong. All costs are measured in 2005 US dollars, and costs and QALY are discounted at 3%. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A.
